Predict your next investment

Asset/Investment Management
nextheracapital.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Nexthera Capital

Nexthera Capital is a healthcare asset manager based in New York.

Nexthera Capital Headquarter Location

900 Third Avenue Suite 1100

New York, New York, 10022,

United States

646-213-7031

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Nexthera Capital News

Sutro Biopharma Raises $85.4M in Series E Funding Round

Jul 26, 2018

Sutro Biopharma, Inc. , a South San Francisco, CA-based developer of a pipeline of novel cancer therapeutics, secured $85.4m in Series E financing. The round was led by Samsara BioCapital and Surveyor Capital (a Citadel company), and supported by current investors, Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Health Investors and new investors Eventide, Nexthera Capital, Vida Ventures and funds managed by Tekla Capital Management LLC, as well as Merck, known as MSD outside the United States and Canada. In conjunction with the funding, Mike Dybbs, PhD, Partner at Samsara BioCapital, will join the Sutro Board of Directors. The company intends to use the funds to develop a pipeline of novel cancer therapeutics, including two internally-developed antibody drug conjugates, or ADCs, known as STRO-001, now in Phase 1 clinical testing for lymphoma and multiple myeloma, and STRO-002, which is expected to enter clinical trials for ovarian and endometrial cancer by early 2019. The proceeds will also be used to further early stage programs and continued platform technology advancement. STRO-001 and STRO-002 were developed using Sutro’s proprietary cell-free protein synthesis and site-specific conjugation platforms. Led by CEO Bill Newell, Sutro Biopharma is a clinical-stage drug discovery, development and manufacturing company creating a broad variety of optimally designed, next-generation protein therapeutics for oncology and autoimmune disorders based on its proprietary integrated cell-free protein synthesis and site-specific conjugation platforms, XpressCF™ and XpressCF+™. To date, the company has designed cytokine-based immuno-oncology therapeutics, ADCs, and bispecific antibodies directed primarily against clinically-validated targets where the current standard of care can be suboptimal. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generation therapeutics. FinSMEs 26/07/2018

Nexthera Capital Investments

1 Investments

Nexthera Capital has made 1 investments. Their latest investment was in Sutro Biopharma as part of their Series E on June 6, 2018.

CBI Logo

Nexthera Capital Investments Activity

investments chart

Nexthera Capital Portfolio Exits

1 Portfolio Exit

Nexthera Capital has 1 portfolio exit. Their latest portfolio exit was Sutro Biopharma on September 27, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/27/2018

IPO

$991

2

Date

9/27/2018

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.